PMH72 HEALTHCARE RESOURCE UTILIZATION (HRU) ASSOCIATED WITH EXTENDED-RELEASE NALTREXONE (XR-NTX) COMPARED WITH OTHER TREATMENTS IN PUBLICLY INSURED PATIENTS WITH OPIOID USE DISORDER (OUD)
نویسندگان
چکیده
منابع مشابه
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX)
OBJECTIVES Once-monthly intramuscular extended-release naltrexone (XR-NTX) has demonstrated efficacy for the prevention of relapse in opioid dependence, providing an alternative to agonist or partial agonist maintenance (ie, methadone and buprenorphine). The question remains, for whom is this unique treatment most efficacious and can patient-treatment matching factors be identified? METHODS A...
متن کاملOpen-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
OBJECTIVES Healthcare professionals (HCPs) with opioid dependence are at risk for relapse and death, particularly in the first year of recovery; however, maintenance treatment with opioid agonists is controversial in this safety-sensitive group. We evaluated long-term safety, tolerability, and treatment outcomes of injectable, intramuscular, extended-release naltrexone (XR-NTX) in opioid-depend...
متن کاملExtended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through...
متن کاملEffects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
BACKGROUND Heightened response to drug-related cues is a hallmark of addiction. Extended-release naltrexone (XR-NTX) is a US Food and Drug Administration-approved pharmacotherapy for relapse prevention in patients with opioid use disorder (OUD). In these patients, XR-NTX has been shown to reduce brain responses to opioid-related visual stimuli. To assess the biomarker potential of this phenomen...
متن کاملWhose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
Background In 2010, Los Angeles County made the decision to offer publicly funded patients receiving treatment for substance use disorders extended-release naltrexone (XR-NTX, brand name “Vivitrol”). Since 2010, over 1200 patients have received at least one dose of extended-release naltrexone. Little is known concerning the differential impact of the medication on those who use it for alcohol u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2020
ISSN: 1098-3015
DOI: 10.1016/j.jval.2020.04.686